30-day average of 20 articles · scale −100 to +100
Across 20 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Aflac news is Slightly Bullish (+11)
on a scale from −100 to +100.
That is up 13 points from the previous 30 days (-2).
📉 Director Joseph Moskowitz sold 600 shares for $74,994 on Nov 9th.
📉 Quarterly revenue dropped 31.0% year-over-year to $4.30 billion.
Slightly Bullish +25
Aflac (NYSE:AFL) Stock: Insider Joseph Moskowitz Sells 600 Shares
AI-generated analysis
Key insights
📉 Director Joseph Moskowitz sold 600 shares for $74,994 under a Rule 10b5-1 trading plan on November 9th.
📈 Aflac reported Q3 EPS of $2.43, significantly beating the consensus estimate of $1.80.
💰 The company generated revenue of $4.30 billion for the quarter, exceeding analyst expectations of $4.12 billion.
📉 Quarterly revenue decreased by 31.0% compared to the same period in the prior year.
💵 Aflac declared a quarterly dividend of $0.64 per share, payable on March 1st with an ex-dividend date of February 17th.
📊 The company achieved a net margin of 21.24% and a return on equity of 12.82% for the quarter.
🏦 Institutional investors own 67.44% of Aflac's outstanding stock as of recent filings.
📉 Analysts maintain an average 'Hold' rating with a consensus price target of $118.73.
📈 Bullish signals
📈Aflac beat quarterly EPS estimates by $0.63, reporting $2.43 per share against a consensus of $1.80.
💰The company exceeded revenue expectations with $4.30 billion reported versus the forecasted $4.12 billion.
💵Aflac increased its quarterly dividend to $0.64 per share, raising the annualized yield to 2.0%.
📈Weiss Ratings upgraded Aflac from a 'buy (b+)' to a 'buy (a-)' rating on November 3rd.
📉 Risk factors
📉Aflac's quarterly revenue declined by 31.0% year-over-year, indicating potential headwinds in its core business.
📉Barclays reaffirmed an 'underweight' rating with a price target of $101.00, citing concerns about the stock.
Article
Aflac Incorporated (NYSE:AFL) Director Joseph Moskowitz sold 600 shares of company stock on November 9th for a total value of $74,994. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, leaving the director with 32,119 shares directly owned. This sale represents a 1.83% decrease in his position and is disclosed via an SEC filing.
The financial services provider reported strong quarterly earnings on November 4th, beating consensus estimates significantly. Aflac posted $2.43 EPS compared to the expected $1.80, driven by revenue of $4.30 billion versus a forecast of $4.12 billion. The company achieved a net margin of 21.24% and a return on equity of 12.82%, though quarterly revenue declined 31.0% year-over-year.
Aflac recently declared a quarterly dividend to be paid on March 1st for shareholders of record on February 17th. The dividend amount is $0.64 per share, representing an increase from the previous quarter's payout and yielding 2.0% annually. Analysts maintain mixed ratings with an average price target of $118.73, while institutional ownership stands at 67.44%.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Aflac Incorporated (NYSE:AFL) Director Joseph Moskowitz sold 12,370 shares of the company on June 22nd at an average price of $116.54 per share, totaling approximately $1.44 million in transaction value. Following this sale, Moskowitz retains ownership of 33,310 shares, representing a 27.08% decrease in his personal stake. The trade was disclosed via an SEC filing and occurred while the stock traded near its 50-day moving average.
The company reported quarterly earnings on April 29th with revenue of $4.24 billion, beating analyst estimates by $40 million. However, the firm posted EPS of $1.75, missing the consensus estimate of $1.80 by five cents. Despite the earnings miss, Aflac achieved a net margin of 25.60% and reported revenue growth of 27.9% year-over-year compared to the prior year's quarter.
Wall Street sentiment remains mixed with a consensus target price of $112.27, though several major brokerages have recently upgraded their ratings or price targets. Notable upgrades include Evercore moving from 'strong sell' to 'strong-buy', Wall Street Zen shifting to 'hold', and Morgan Stanley raising its price objective to $125.00. Institutional ownership remains high at 67.44%, with significant activity from hedge funds like Western Wealth Management and Empowered Funds in the first quarter.
📉 Director sold 12,370 shares for $1.44 million.
💰 Q1 revenue hit $4.24 billion, beating estimates.
📈 Revenue grew 27.9% year-over-year to $4.24B.
🏦 Morgan Stanley raised target to $125.00.
📊 Stock trades at PE 13.40 with $60B market cap.
📉 Director Joseph Moskowitz sold 12,370 shares of Aflac for $1.44 million, reducing his personal ownership by 27.08%.
💰 The company reported Q1 revenue of $4.24 billion, surpassing analyst expectations of $4.20 billion.
📉 Earnings per share came in at $1.75, missing the consensus estimate of $1.80 by $0.05.
📈 Revenue grew 27.9% year-over-year compared to the same quarter in the prior fiscal year.
🏦 Morgan Stanley raised its price target to $125.00 and maintained an 'equal weight' rating on the stock.
🚀 Evercore upgraded Aflac from a 'strong sell' to a 'strong-buy' rating in April.
📉 Wall Street Zen upgraded the stock from 'sell' to 'hold' following recent performance data.
🏛️ Institutional ownership stands at 67.44%, with hedge funds increasing stakes significantly in Q1.
📊 The stock currently trades with a PE ratio of 13.40 and a market capitalization of $60.08 billion.
📉 Analyst consensus target price is set at $112.27, slightly below the current trading levels.
Aflac Inc. shares reached a new all-time high of approximately $119.85 on the New York Stock Exchange, trading near record levels around $118.40 as of June 25, 2026. This milestone follows a robust multi-year streak of dividend increases and steady earnings performance, with the stock currently valued at a market capitalization of roughly $60.26 billion.
Despite the positive share price momentum, Wall Street sentiment remains cautious. A consensus of 11 analysts rates the stock as a 'Hold,' with an average price target of $112.09 sitting below current trading prices. The company maintains a moderate valuation profile with a price-to-earnings multiple near 13.4 and a dividend yield around 2 percent.
Fundamentally, Aflac reported strong first-quarter 2026 revenue of approximately $4.35 billion, beating analyst expectations of $4.18 billion. However, adjusted earnings per slightly missed consensus estimates, resulting in a mixed but resilient quarterly picture for the supplemental health and life insurance provider.
Japan Post Holdings Co., Ltd., acting as a reporting person for AFLAC Inc. (NYSE: AFL), disclosed two open-market sales of its common stock executed on June 22, 2026. The transactions involved the sale of a total of 27,845 shares held within the J&A Alliance Trust, with one block comprising 4,429 shares and another consisting of 23,416 shares.
The sales were executed at weighted average prices ranging between $116.18 and $117.72 per share. Following these transactions, the trust continues to hold over 50 million AFLAC shares indirectly. The filing clarifies that while Japan Post may be deemed a beneficial owner due to its role as sole settlor and beneficiary, all involved entities expressly disclaim beneficial ownership except for their pecuniary interest.
The report details the specific transaction codes and price ranges for each sale block, noting that the shares were sold on the open market rather than through private agreements. The filing is a standard Form 4 submitted to the SEC under Section 16(a) of the Securities Exchange Act of 1934, confirming routine insider trading activity by an affiliated entity.
This news represents a neutral-to-slightly-negative signal for investors as open-market sales by insiders or affiliates can increase supply and potentially exert short-term downward pressure on the stock price. However, the volume sold is negligible relative to the company's total outstanding shares of over 50 million, suggesting these are likely routine portfolio adjustments rather than a significant loss of confidence in the company's long-term prospects.
📅 Japan Post sold 27,845 AFLAC shares on June 22, 2026.
💰 Weighted average sale price ranged from $116.18 to $117.72.
🏦 Shares held by J&A Alliance Trust as beneficial owner.
📊 Trust retains over 50 million AFLAC shares after sales.
📝 Filing submitted under Section 16(a) of Securities Exchange Act.
📅 Japan Post Holdings reported two open-market sales of AFLAC common stock executed on June 22, 2026.
💰 The total volume sold was 27,845 shares, split into blocks of 4,429 and 23,416 shares.
📉 Shares were sold at weighted average prices ranging from $116.18 to $117.72 per share.
🏦 The shares are held by J&A Alliance Holdings Corporation as trustee of the J&A Alliance Trust.
🤝 Japan Post is deemed a beneficial owner through its role as sole settlor and beneficiary of the trust.
⚖️ All involved entities expressly disclaim beneficial ownership except to the extent of their pecuniary interest.
📊 The trust continues to hold over 50 million AFLAC shares indirectly after these sales.
📝 The filing is a Form 4 submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934.
🔄 Transactions are coded as 'S' indicating standard open-market sales rather than private deals.
Risk Factors
Japan Post sold 27,845 shares on June 22, 2026.
Insider sales signal lack of confidence in near-term prices.
Sale adds liquidity causing short-term downward price pressure.
Risk Factors
Japan Post Holdings sold 27,845 shares of AFLAC common stock on June 22, 2026, adding supply to the market.
Open-market sales by insiders or affiliates can signal a lack of confidence in near-term price appreciation.
The sale of nearly 28,000 shares represents a small but measurable increase in available liquidity that could exert short-term downward pressure on the stock price.
Hsbc Holdings PLC increased its stake in Aflac Incorporated by 5.8% during the fourth quarter, acquiring an additional 58,018 shares to own a total of 1,061,308 shares valued at approximately $117.19 million. This represents about 0.21% of Aflac's outstanding stock. Other institutional investors also adjusted their positions, with Pure Financial Advisors lifting holdings by 2.6%, while several smaller firms like Bayban and Reflection Asset Management established new stakes ranging from $34,000 to $52,000.
Institutional ownership of Aflac stands at 67.44%. Meanwhile, major shareholder Post Holdings Co. Ltd. Japan sold 30,000 shares on June 16th for roughly $3.52 million under a pre-arranged trading plan. Over the last ninety days, insiders have collectively sold over 1 million shares worth approximately $118.3 million, though corporate insider ownership remains at 0.80%.
Analyst sentiment is mixed with varying price targets and ratings. Piper Sandler raised its target to $130 with an overweight rating, while Morgan Stanley increased its target to $125. Conversely, Wells Fargo lowered its target to $111 with an equal weight rating, and Mizuho set a lower objective at $104. The consensus price target is currently $112.27 with an average rating of Hold.
Aflac recently paid a quarterly dividend of $0.61 per share on June 1st to stockholders of record as of May 20th, representing a 2.1% yield and a payout ratio of 27.70%. Financial metrics show the company trading near its 50-day moving average with a market capitalization of $58.79 billion, a P/E ratio of 13.11, and a beta of 0.61.
📈 HSBC Holdings increased Aflac stake by 5.8% to 1,061,308 shares.
💰 Post Holdings Japan sold 30,000 shares for $3.52 million recently.
📉 Insiders sold over 1 million shares worth $118.3 million in 90 days.
💵 Aflac pays $0.61 quarterly dividend with 2.1% annualized yield.
🎯 Analyst consensus price target is $112.27 with Hold rating.
📈 Hsbc Holdings PLC increased its Aflac position by 5.8% in Q4, adding 58,018 shares to a total holding of 1,061,308 shares valued at $117.19 million.
🏦 Institutional investors own 67.44% of Aflac's stock, with Pure Financial Advisors increasing its stake by 2.6% to 10,790 shares.
💰 Post Holdings Co. Ltd. Japan sold 30,000 shares for $3.52 million on June 16th under a Rule 10b5-1 trading plan.
📉 Insiders have sold over 1 million shares worth $118.3 million in the last ninety days, though they still own 0.80% of the stock.
💵 Aflac paid a $0.61 quarterly dividend on June 1st with an annualized yield of 2.1% and a payout ratio of 27.70%.
📊 The company trades at a P/E ratio of 13.11 with a market cap of $58.79 billion and a beta of 0.61.
🎯 Piper Sandler raised its price target to $130 with an overweight rating, while Morgan Stanley increased its target to $125.
⚖️ Wells Fargo lowered its price target to $111 with an equal weight rating, and Mizuho set a lower objective at $104.
📉 The consensus analyst price target is $112.27 with an average rating of Hold across the industry.
Bullish Signals
Hsbc Holdings increased stake by 5.8%, holding 1,061,308 shares valued at $117.19 million.
Pure Financial Advisors lifted holdings by 2.6%, owning 10,790 shares valued at $1.19 million.
Piper Sandler raised price target to $130.00 with overweight rating.
Morgan Stanley increased price target to $125.00 with equal weight rating.
Keefe Bruyette raised price target to $115.00 with market perform rating.
Aflac paid $0.61 dividend on June 1st, yielding 2.1%.
Risk Factors
Target price cut to $111.00 by Wells Fargo.
Mizuho lowered objective to $104.00 on May 4th.
Insiders sold 1,026,856 shares worth $118M recently.
Bullish Signals
Hsbc Holdings PLC increased its stake by 5.8% in Q4, adding 58,018 shares to a total holding of 1,061,308 shares valued at $117.19 million.
Pure Financial Advisors LLC lifted its holdings by 2.6% during the fourth quarter, now owning 10,790 shares valued at $1.19 million.
Piper Sandler raised its price target on Aflac from $125.00 to $130.00 and reaffirmed an overweight rating.
Morgan Stanley increased its price target from $120.00 to $125.00 and maintained an equal weight rating.
Keefe, Bruyette & Woods raised their price target from $113.00 to $115.00 with a market perform rating.
Aflac recently paid a quarterly dividend of $0.61 per share on June 1st, representing a 2.1% yield.
Risk Factors
Wells Fargo & Company decreased their target price on shares of Aflac from $116.00 to $111.00 and set an equal weight rating.
Mizuho set a lower price objective of $104.00 in a report issued on Monday, May 4th.
Over the last ninety days, insiders have sold 1,026,856 shares worth $118,318,678, indicating some insider selling pressure.
Aflac Inc.'s Cancer Protection Assurance is a signature supplemental health product designed to provide cash benefits directly to policyholders following a covered cancer diagnosis. Unlike traditional medical insurance that reimburses providers, this voluntary policy pays fixed lump-sum or scheduled payments directly to the insured for use on medical bills, travel, childcare, and lost income. It serves as a financial safety net specifically targeting the out-of-pocket cost shock associated with cancer treatment.
The product is primarily distributed through the worksite benefits channel, where premiums are often deducted from payroll. Eligibility varies by state, with policies generally renewable as long as premiums are paid. The plan covers specific events such as initial diagnosis, hospital confinement, chemotherapy, and radiation, with optional riders available for extended treatment or wellness screenings. It is positioned to complement broader critical illness plans by offering granular, treatment-linked benefits.
Financially, the cancer insurance line contributes to Aflac's US segment earnings alongside accident and hospital indemnity coverage, though the company's largest earnings driver remains its Japan business. Management views US supplemental health products as having steady demand due to rising deductibles in major medical plans. The article notes that shares traded around $89 on June 13, 2026, reflecting investor confidence in Aflac's resilient cash flows from its mix of Japanese life insurance and US voluntary benefits.
🏥 Pays direct cash benefits upon covered cancer diagnosis.
💰 Covers non-medical costs like lodging and lost income.
👔 Sold via employers as voluntary supplemental policies.
📈 Shares traded at $89 on June 13, 2026.
🛡️ Offers optional riders for extended treatment benefits.
🏥 Aflac Cancer Protection Assurance provides direct cash benefits to policyholders upon a covered cancer diagnosis rather than reimbursing medical providers.
💰 Benefits are flexible and can be used for non-medical costs like transportation, lodging, childcare, and lost income during treatment.
👔 The product is primarily sold through employers via payroll deduction in most US states as a voluntary supplemental policy.
📅 Coverage includes specific events such as initial diagnosis, hospital confinement, chemotherapy, radiation, and follow-up care.
🛡️ Optional riders allow for extended benefits for continuous treatment or wellness incentives tied to routine cancer screenings.
💵 Financially, the cancer line supports Aflac's US segment earnings while the company relies on its Japan business for the majority of profits.
📈 Shares traded at approximately $89 on June 13, 2026, indicating market stability in Aflac's mixed business model.
Bullish Signals
Direct cash payments provide immediate liquidity for medical and non-medical expenses.
Flexible benefit structures allow tailoring coverage to specific budgetary needs.
Rapid claims processing and digital filing address customer pain points.
Wellness benefits encourage preventive care while maintaining recurring engagement.
Reinforces Aflac's strong brand positioning as a leader in income protection.
Risk Factors
State-specific exclusions, waiting periods, and benefit caps apply.
Voluntary supplemental policy; does not replace major medical insurance.
US financial performance secondary to primary Japan earnings.
Bullish Signals
The policy offers direct cash payments to the insured, providing immediate liquidity for medical and non-medical expenses during a crisis.
Flexible benefit structures allow employers and individuals to tailor coverage levels and optional riders to specific budgetary needs.
Rapid claims processing and digital filing capabilities address customer pain points regarding the need for quick financial support.
Wellness benefits tied to routine screenings encourage preventive care while maintaining recurring engagement with the policy.
The product reinforces Aflac's strong brand positioning as a leader in targeted income protection within the worksite benefits channel.
Risk Factors
Policies are subject to state-specific exclusions, waiting periods, and benefit caps that vary by jurisdiction.
As a voluntary supplemental policy, it is not intended to replace major medical insurance coverage.
Financial performance of the US segment is secondary to the company's primary earnings driver in Japan.
On June 11, 2026, entities associated with Japan Post Holdings Co., Ltd. executed open-market sales of 48,500 shares of AFLAC Inc. (AFL) common stock through the J&A Alliance Trust. The transactions were split into two tranches: one involving 22,268 shares at a weighted average price of $116.62 per share, and another involving 26,232 shares at a weighted average price of $117.69 per share.
The filings indicate that the securities are held directly by J&A Alliance Holdings Corporation acting as trustee for the J&A Alliance Trust. While Japan Post Holdings is deemed to beneficially own these shares due to its role as the sole settlor and beneficiary, the entities expressly disclaim beneficial ownership beyond their pecuniary interests in the trust structure.
Following these sales, the filing reports that 51,093,967 shares of AFLAC common stock remain indirectly held by the trust. This remaining position suggests that the recent sale represents a relatively small portion of the total reported stake held by Japan Post and its affiliated entities.
📅 Transactions occurred on June 11, 2026.
📉 Sold 48,500 shares via J&A Alliance Trust.
💰 Weighted average sale prices ranged $116.31-$118.17.
🏦 Japan Post Holdings is deemed beneficial owner.
📊 Approximately 51.09 million shares remain indirectly held.
📅 Transactions occurred on June 11, 2026, involving indirect open-market sales of AFLAC shares.
📉 A total of 48,500 shares were sold across two distinct tranches via the J&A Alliance Trust.
💰 The weighted average sale prices ranged between $116.31 and $118.17 per share.
🏦 Japan Post Holdings is deemed a beneficial owner through its role as settlor and beneficiary of the trust.
📊 Approximately 51.09 million shares remain indirectly held after the transaction.
⚖️ Related parties disclaim beneficial ownership except to the extent of their pecuniary interest.
Bullish Signals
Japan Post holds a significant long-term stake in AFLAC.
Transaction via trust suggests strategic institutional holding.
Risk Factors
Japan Post sold 48,500 shares, reducing institutional ownership.
Sale price of $116.31-$118.17 may be below current market.
Bullish Signals
The sale represents a small fraction of the total reported position, indicating Japan Post maintains a significant long-term stake in AFLAC.
The transaction was executed via a trust structure, which often implies a strategic or institutional holding rather than a panic-driven liquidation.
Risk Factors
Japan Post Holdings reduced its indirect stake by selling 48,500 shares, signaling a slight decrease in institutional ownership.
The sale was executed at weighted average prices between $116.31 and $118.17, which may be near or below current market levels depending on real-time pricing.
AFLAC Inc. reported an insider filing indicating that entities associated with Japan Post Holdings Co., Ltd. indirectly sold 26,500 shares of AFLAC common stock via open-market transactions. The sales were executed by J&A Alliance Holdings Corporation acting as the trustee of the J&A Alliance Trust. These transactions represent a reduction in holdings held indirectly through a trust structure rather than a direct sale by Japan Post Holdings itself.
The filing details two specific trades: 4,797 shares sold at a weighted average price of $116.25 per share and 21,703 shares sold at a weighted average price of $117.16 per share. The total transaction prices ranged between $115.84 and $117.635 across multiple trades. Following these sales, the beneficial ownership count for the trust decreased from approximately 51.14 million shares to 51.12 million shares.
The reporting entities, including General Incorporated Association J&A Alliance and individuals Kenji Sano and Tetsuya Numaguchi, may be deemed beneficial owners but expressly disclaim beneficial ownership beyond their pecuniary interest. Japan Post Holdings is listed as the sole settlor and beneficiary of the trust, potentially allowing it to be deemed a beneficial owner despite the disclaimer. The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934.
📉 Japan Post trust sold 26,500 AFLAC shares via open market.
💰 Transactions averaged $116.25 and $117.16 per share respectively.
🏦 Shares held by J&A Alliance Trust as beneficial owner.
📅 SEC Form 4 filed June 12, 2026.
📊 Indirect holdings dropped from 51.1M to 51.1M shares.
📉 Japan Post Holdings linked trust sold 26,500 AFLAC shares via open-market transactions.
💰 First transaction involved 4,797 shares at an average price of $116.25 per share.
💰 Second transaction involved 21,703 shares at an average price of $117.16 per share.
🏦 Shares are held by J&A Alliance Holdings Corporation as trustee of the J&A Alliance Trust.
⚖️ Entities including Japan Post may be deemed beneficial owners but disclaim full ownership rights.
📅 Filing was submitted on June 12, 2026, pursuant to SEC Form 4 requirements.
📊 Total indirect holdings dropped from 51,137,938 shares to 51,116,235 shares post-sale.
Bullish Signals
Sold at $116.25–$117.16, aligning with recent market ranges.
Japan Post Holdings remains a significant indirect holder.
Risk Factors
Japan Post sold 26,500 shares, signaling reduced confidence.
Trust structure obscures true ownership intent behind sale.
Bullish Signals
The sale was executed via open-market transactions at prices ($116.25–$117.16) that align with recent market ranges, suggesting no panic selling or distressed liquidation.
Japan Post Holdings remains a significant indirect holder through the trust structure, maintaining substantial exposure to AFLAC despite the partial reduction.
Risk Factors
The sale of 26,500 shares by a major institutional entity linked to Japan Post Holdings could be interpreted as a slight reduction in confidence or portfolio rebalancing by a key shareholder.
The indirect nature of the holding via a trust with disclaimed beneficial ownership adds complexity to understanding the true intent behind the sale.
Piper Sandler analyst John Barnidge raised his price target on Aflac Incorporated (NYSE: AFL) from $125 to $130 and maintained an Overweight rating as of May 26, citing the stock's recent performance and the passage of time. The firm adopted a bottom-up approach following first-quarter results, concluding that investors should favor insurance carriers over brokers due to stronger-than-expected underwriting performance for carriers versus weaker organic growth from brokers. Aflac provides financial protection through its subsidiaries in the United States and Japan, with its primary business focused on supplemental health and life insurance products.
📈 Piper Sandler raised Aflac's price target to $130 with an Overweight rating.
🏢 Analysts favor insurance carriers over brokers due to stronger underwriting performance.
💰 Aflac ranks among top long-term dividend stocks recommended by billionaires.
📈 Piper Sandler analyst John Barnidge raised the price target on Aflac (AFL) from $125 to $130.
⚖️ The firm maintained an Overweight rating on Aflac following the adjustment.
🏢 Piper Sandler prefers investing in insurance carriers over brokers based on recent performance data.
📉 Underwriting performance for carriers was stronger than expected, while brokers showed weaker organic growth.
🌍 Aflac provides supplemental health and life insurance through subsidiaries in the United States and Japan.
💰 Aflac is included among the 10 Best Long-Term Dividend Stocks to Invest In According to Billionaires.
⚠️ The article includes a promotional disclaimer suggesting AI stocks may offer higher returns than AFL.
Bullish Signals
Analyst raised Aflac (NYSE: AFL) price target to $130.
Firm maintains Overweight rating on Aflac stock.
Aflac listed among billionaires' top 10 dividend stocks.
Piper Sandler favors insurers over brokers due to broker sector weakness.
Alternative AI stocks show higher upside potential than AFL.
Bullish Signals
Piper Sandler analyst John Barnidge raised the price target on Aflac (NYSE: AFL) to $130 from $125, signaling increased upside potential.
The firm maintained an Overweight rating on Aflac, indicating continued confidence in the stock's performance.
Aflac is included among the 10 Best Long-Term Dividend Stocks to Invest In According to Billionaires, highlighting its appeal for income-focused investors.
Underwriting performance came in stronger than expected for insurance carriers like Aflac following first-quarter results.
Risk Factors
The article explicitly acknowledges risk and potential for AFL as an investment, suggesting caution despite the positive analyst rating.
Piper Sandler favors insurance carriers over brokers due to weaker organic growth results in the broker sector, implying a relative competitive disadvantage or structural weakness for broker-focused strategies.
The text promotes alternative AI stocks with '10,000% upside potential' as more promising than AFL, suggesting AFL may offer lower returns or shorter time frames compared to emerging AI opportunities.
Aflac Incorporated issued yen-denominated senior notes totaling ¥65.9 billion on May 28, 2026, with maturities ranging from 2029 to 2036 and coupon rates between 2.117% and 3.482%. The notes carry semi-annual interest payments starting November 28, 2026, and were sold in a registered public offering under an existing shelf registration. They are structured with optional par redemption dates ahead of final maturity and rank as the company's general unsecured senior obligations.
Aflac plans to use the net proceeds for general corporate purposes, which enhances financial flexibility and may support funding needs across its insurance operations while maintaining customary protections for noteholders through standard indenture terms and events of default. This move underscores Aflac's continued access to Japanese capital markets and its reliance on capital markets to fund growth, maintain liquidity, and optimize its capital structure for meeting long-term policyholder obligations.
Aflac is a Georgia-based financial services company operating in the insurance industry, best known for its supplemental health and life insurance products. The company focuses on providing insurance solutions to individuals and businesses, with a significant presence in Japan and the United States. Analysts rate AFLAC stock as a Buy with a $130.00 price target, noting strong financial quality metrics including high margins, solid ROE, and manageable leverage, though earnings sensitivity and uneven top-line/FCF consistency remain constraints.
📅 Aflac issued ¥65.9B yen notes maturing 2029–2036 with 2.1%–3.5% coupons.
💰 Proceeds fund general corporate purposes to enhance financial flexibility and liquidity.
⚠️ Analysts rate stock a Buy despite earnings sensitivity to Japan's premium pressure.
📅 On May 28, 2026, Aflac Incorporated issued yen-denominated senior notes totaling ¥65.9 billion.
📈 The new debt instruments have maturities ranging from 2029 to 2036 with coupon rates between 2.117% and 3.482%.
💰 Interest payments on the notes are scheduled for semi-annual intervals starting November 28, 2026.
🔄 The offering was structured as a registered public sale under an existing shelf registration with optional redemption dates.
🏦 These securities rank as general unsecured senior obligations consistent with Aflac's other senior debt.
💼 Net proceeds from the issuance will be used for general corporate purposes to enhance financial flexibility.
🇯🇵 The transaction underscores Aflac's continued access to Japanese capital markets for funding its insurance operations.
📊 Analysts currently rate AFLAC stock as a Buy with a price target of $130.00.
🤖 AI analyst Spark rates AFL as an Outperform based on financial quality metrics like high margins and solid ROE.
⚠️ Key constraints identified include uneven top-line consistency and earnings sensitivity to Japan's earned-premium pressure.
📉 The company trades at a P/E ratio of approximately 13.8 with a yield of around 2%.
🏢 Aflac is a Georgia-based financial services firm best known for supplemental health and life insurance products.
🌍 The company maintains significant operational presence in both Japan and the United States markets.
💸 Capital market reliance helps Aflac fund growth, maintain liquidity, and optimize its capital structure.
🛡️ Standard indenture terms and events of default are maintained to protect noteholders' interests.
Bullish Signals
Aflac issued ¥65.9B yen notes, showing strong capital market access.
Net proceeds support general corporate purposes and operational funding needs.
Analysts rate AFLAC Buy with a $130 price target.
TipRanks AI rates AFL Outperform citing high margins and solid ROE.
Stock trades at ~13.8 P/E with a ~2% yield.
Risk Factors
Uneven top-line/FCF consistency and earnings volatility constrain Aflac.
Japan premium pressure and reserve/investment impacts threaten profitability.
Bullish Signals
Aflac successfully issued ¥65.9 billion in yen-denominated senior notes, demonstrating continued strong access to Japanese capital markets.
The company plans to use the net proceeds for general corporate purposes, which enhances financial flexibility and supports funding needs across its insurance operations.
Analysts maintain a Buy rating on AFLAC stock with a $130.00 price target, indicating confidence in the company's prospects.
TipRanks' AI Analyst rates AFL as an Outperform, highlighting strong financial quality metrics including high margins and solid ROE.
The stock trades at a reasonable valuation with a P/E ratio of approximately 13.8 and offers a ~2% yield to investors.
Risk Factors
Analysts note uneven top-line/FCF consistency and earnings sensitivity/volatility as main constraints on Aflac's financial quality.
The company faces Japan earned-premium pressure, reserve/investment impacts, and higher U.S. expenses which could impact profitability.
Aflac Incorporated issued yen-denominated senior notes totaling ¥65.9 billion on May 28, 2026, with maturities extending from 2029 to 2036 and coupon rates ranging between 2.117% and 3.482%. The securities carry semi-annual interest payments beginning November 28, 2026, and were sold in a registered public offering under an existing shelf registration with optional par redemption dates prior to final maturity. These notes rank as the company's general unsecured senior obligations, aligning them with its other senior debt while underscoring continued access to Japanese capital markets. Proceeds from the issuance will be used for general corporate purposes to enhance financial flexibility and support funding needs across insurance operations in Japan and the United States.
Analyst coverage highlights a Buy rating with a $130.00 price target, noting strong financial quality metrics including high margins, solid return on equity, and manageable leverage. The stock trades at a P/E ratio of approximately 13.8 with a yield near 2%, though constraints include uneven top-line and free cash flow consistency alongside earnings sensitivity to Japan earned-premium pressure, reserve impacts, and higher U.S. expenses. Aflac operates as a Georgia-based financial services company specializing in supplemental health and life insurance products with significant presence in both Japan and the U.S., utilizing capital markets to fund growth, maintain liquidity, and optimize its capital structure for long-term policyholder obligations.
📅 Aflac issued ¥65.9B yen notes maturing 2029–2036 with coupons up to 3.482%.
💰 Proceeds fund general corporate purposes while maintaining unsecured senior debt status.
⚠️ Analysts rate stock a Buy despite earnings sensitivity to Japan's premium pressure.
📅 On May 28, 2026, Aflac Incorporated issued yen-denominated senior notes totaling ¥65.9 billion.
📈 The new debt instruments have maturities ranging from 2029 to 2036 with coupon rates between 2.117% and 3.482%.
💰 Interest payments on the notes are scheduled for semi-annual intervals starting November 28, 2026.
🔄 The offering was structured as a registered public sale under an existing shelf registration with optional redemption dates.
🏦 These securities rank as general unsecured senior obligations consistent with Aflac's other senior debt.
💼 Net proceeds from the issuance will be used for general corporate purposes to enhance financial flexibility.
🇯🇵 The transaction underscores Aflac's continued access to Japanese capital markets for funding its insurance operations.
📊 Analysts currently rate AFLAC stock as a Buy with a price target of $130.00 according to TipRanks data.
🤖 Spark AI Analyst rates AFL as an Outperform based on financial quality metrics like margins and ROE.
⚠️ Key constraints identified include uneven top-line consistency and earnings sensitivity to Japan's earned-premium pressure.
📉 The company faces valuation considerations with a P/E ratio of approximately 13.8 and a yield of around 2%.
🏢 Aflac is a Georgia-based financial services firm best known for supplemental health and life insurance products.
🌍 The company maintains significant operational presence in both Japan and the United States markets.
💸 Capital market reliance helps Aflac fund growth, maintain liquidity, and optimize its capital structure.
🛡️ Standard indenture terms and events of default are maintained to protect noteholders' interests.
Bullish Signals
Aflac issued ¥65.9B yen notes, showing strong capital market access.
Net proceeds support general corporate purposes and insurance funding needs.
Analysts rate AFLAC Buy with a $130 price target.
TipRanks AI rates AFL Outperform citing high margins and solid ROE.
Stock trades at ~13.8 P/E with a ~2% yield.
Risk Factors
Japan pressure and investment impacts cause earnings volatility.
Aflac successfully issued ¥65.9 billion in yen-denominated senior notes, demonstrating continued strong access to Japanese capital markets.
The company plans to use net proceeds for general corporate purposes, enhancing financial flexibility and supporting funding needs across its insurance operations.
Analysts maintain a Buy rating on AFLAC stock with a $130.00 price target, indicating confidence in the company's prospects.
TipRanks' AI Analyst rates AFL as an Outperform, highlighting strong financial quality metrics including high margins and solid ROE.
The stock trades at a reasonable valuation with a P/E ratio of approximately 13.8 and offers a ~2% yield to investors.
Risk Factors
Aflac faces earnings sensitivity and volatility risks due to Japan earned-premium pressure, reserve/investment impacts, and higher U.S. expenses.
The company's top-line and free cash flow consistency is described as uneven, raising concerns about stable revenue generation.
Issuing yen-denominated senior notes with maturities extending to 2036 increases long-term debt obligations and refinancing risk over the next decade.
AFLAC stock has gained 11.7% over the last year, significantly underperforming the S&P 500 which rose 27.2%. Analysts currently hold a neutral rating on the diversified insurance company, with a mean target price of $112.07 per share, placing the current stock price just 0.5% away from that consensus valuation. The company trades at a trailing P/E ratio of 12.9 and a forward P/E of 14.8, both substantially lower than the S&P 500 averages of 29.3 and implied future growth expectations respectively. Valuation metrics also show AFLAC trading at a Price to Book ratio of 1.92 compared to the broader market average of 4.74, while its sector peers in Finance average a P/E of 15.92 and a P/B of 1.78.
Financial performance highlights include reported year-over-year quarterly earnings growth of 3860.0% and gross profit margins of 0.5%, alongside a free cash flow generation of $4.92 billion over the last quarter. The company operates through two primary segments: Aflac Japan, which offers cancer, medical, nursing care, whole life, and other specialized insurance products, and Aflac U.S., which provides accident, disability, critical illness, dental, vision, and life insurance to individuals, families, and business owners. Distribution channels include individual agents, corporate agencies, banks, and brokers across both domestic markets. Founded in 1955 and headquartered in Columbus, Georgia, the firm continues to expand its product suite to include hearing, pet, Medicare supplement, and absence management insurance options.
📈 AFLAC underperformed the S&P 500, gaining 11.7% versus a 27.2% market rise.
💰 Stock trades at $112.64 with a "Hold" rating and analyst target of $112.07.
📊 Valuation metrics show low P/E (12.9) and P/B (1.92) ratios compared to the S&P 500.
🏥 Company offers supplemental insurance in Japan and the U.S. via agents and corporate channels.
⚠️ Past performance is unreliable; investors should conduct independent analysis before trading.
📈 AFLAC stock has gained 11.7% over the last year, significantly underperforming the S&P 500 which rose 27.2%.
💰 The current share price is $112.64, with an average analyst target price of $112.07 and a "Hold" rating.
📊 AFLAC trades at a trailing P/E ratio of 12.9 compared to the S&P 500 average of 29.3.
📉 The company's Price to Book (P/B) ratio is 1.92, well below the S&P 500 average of 4.74.
🏢 AFLAC operates in the Finance sector with a sector-average P/E of 15.92 and P/B of 1.78.
💵 Trailing earnings per share (EPS) are reported at $8.75, while forward EPS is projected at $7.60.
📉 The forward P/E ratio stands at 14.8, indicating expected earnings growth relative to current valuation.
AFLAC has reported year-over-year quarterly earnings growth of 3860.0%, indicating a significant positive shift in profitability.
The company generated $4.92 Billion in free cash flow over the last quarter, demonstrating strong liquidity and operational efficiency.
AFLAC trades at a trailing P/E ratio of 12.9 and a forward P/E of 14.8, which are significantly lower than the S&P 500 average of 29.3, suggesting potential value.
The company's Price to Book ratio of 1.92 is below the S&P 500 average of 4.74 and aligns closely with the Finance sector average of 1.78, indicating a reasonable valuation relative to peers.
Risk Factors
AFLAC has significantly underperformed the broader market, rising only 11.7% over the last year compared to the S&P 500's gain of 27.2%.
Analysts maintain a 'hold' rating with a mean target price of $112.07, which is below the current trading price of $112.64, suggesting limited upside potential.
The company trades at a trailing P/E ratio of 12.9 and forward P/E of 14.8, both substantially lower than the S&P 500 average of 29.3 and the Finance sector average of 15.92, indicating market skepticism about future earnings growth.
AFLAC's Price to Book ratio of 1.92 is less than half the S&P 500 average of 4.74 and below the Finance sector average of 1.78, reflecting a low valuation relative to assets.
The reported year-over-year quarterly earnings growth of 3860.0% appears anomalous or non-recurring given the extremely low gross profit margin of just 0.5%, raising concerns about the quality and sustainability of earnings.
Despite high free cash flow, the combination of low valuation multiples and weak relative performance suggests the stock may be priced for stagnation rather than growth.
Aflac Incorporated (AFL) successfully raised ¥65.9 billion, approximately $415 million, in the Japanese bond market on Thursday through a four-part yen bond offering. This issuance was smaller than the ¥74.9 billion raised in 2025 but secured favorable terms with a 3.482% coupon on the 10-year tranche, indicating continued investor demand for foreign corporate debt despite rising global borrowing costs. The deal aligns with a broader trend of overseas borrowers, including Berkshire Hathaway and Alphabet, expanding their activity in Japan's credit market to fund capital-intensive projects like AI and data center expansion.
Operationally, Aflac remains heavily tied to Japan through its supplemental health and life insurance products. In the first quarter, adjusted net investment income at Aflac Japan increased 0.9% year over year to $591 million, while new annualized premium sales jumped 25.5% driven by strong demand for specific product lines such as Anshin Palette, Miraito, and Tsumitasu. Although net earned premiums slipped 6.4% to $1.6 billion, the company's shares have gained 6.3% year-to-date, outperforming the broader industry average of 6.1%.
📈 Aflac raised ¥65.9 billion in yen bonds with a 3.482% coupon rate.
🌐 Foreign firms like Alphabet are expanding activity in Japan's credit market.
📉 Aflac Japan premiums fell 6.4%, though new sales jumped 25.5%.
📈 Shares gained 6.3% year-to-date, slightly outperforming the broader industry.
🔍 Analysts suggest CNO Financial Group is a better-ranked alternative buy.
📈 Aflac raised ¥65.9 billion ($415 million) in a four-part yen bond offering on Thursday, returning to Japan's debt market.
💰 The 10-year tranche of the issuance carried a coupon rate of 3.482%, reflecting favorable terms despite rising global borrowing costs.
📉 This year's deal was smaller than the ¥74.9 billion issued in 2025, though it signals continued demand from Japanese investors for foreign corporate debt.
🌐 Aflac is part of a broader trend of overseas borrowers, including Berkshire Hathaway and Alphabet, expanding their activity in Japan's credit market.
🏢 Alphabet recently made headlines with its first-ever ¥576.5 billion yen bond sale, the largest by a non-Japanese company to date.
🇯🇵 Aflac remains heavily tied to Japan through supplemental health and life insurance products that generate a significant share of its earnings.
💵 In the first quarter, adjusted net investment income at Aflac Japan rose 0.9% year-over-year to $591 million.
📉 Net earned premiums for Aflac Japan slipped 6.4% to $1.6 billion in the same period.
🆙 New annualized premium sales jumped 25.5%, driven by strong demand for products like Anshin Palette, Miraito, and Tsumitasu.
📈 Aflac shares have gained 6.3% year-to-date, slightly outperforming the broader industry's 6.1% growth.
🏷️ The stock currently holds a Zacks Rank #3 (Hold) rating according to Zacks Investment Research.
🔍 Analysts note that CNO Financial Group is a better-ranked alternative in the Finance space with a Zacks Rank #2 (Buy).
📊 Zacks' Consensus Estimate for CNO Financial's current-year earnings is pegged at $4.47 per share, indicating 9.6% year-over-year growth.
🚀 Zacks Research has released a list of five stocks with the greatest probability of gaining +100% or more in the coming months.
🛰️ The top pick from that list is a little-known satellite-based communications firm projected to become a trillion-dollar industry.
📉 Aflac's stock price data is provided by BSB-Software, while Zacks has averaged +23.89% annual returns since 1988.
Bullish Signals
Aflac raised ¥65.9B ($415M) in Japanese bonds.
Secured 3.482% coupon on 10-year tranche.
Adjusted net investment income rose 0.9% to $591M.
Stock gained only 6.3% YTD, trailing industry average growth.
Bullish Signals
Aflac successfully raised ¥65.9 billion ($415 million) in the Japanese bond market, demonstrating continued access to capital despite a smaller issuance size compared to the previous year.
The company secured funding on favorable terms with a 3.482% coupon on its 10-year tranche, indicating strong investor demand for Aflac's debt even amid rising global borrowing costs.
Aflac Japan reported adjusted net investment income of $591 million in the first quarter, representing a 0.9% year-over-year increase.
New annualized premium sales jumped 25.5% in the first quarter, driven by strong demand for specific products including Anshin Palette, Miraito, and Tsumitasu.
Aflac shares have gained 6.3% year-to-date, outperforming the broader industry average growth of 6.1%.
The company remains a beneficiary of the broader trend of foreign issuers expanding activity in Japan's credit market, alongside peers like Alphabet and Berkshire Hathaway.
Risk Factors
Aflac's latest bond issuance of ¥65.9 billion was significantly smaller than the ¥74.9 billion raised in 2025, indicating a contraction in capital raising activity.
Net earned premiums slipped 6.4% to $1.6 billion in the first quarter, signaling a decline in core insurance revenue despite growth in new sales.
Aflac currently holds a Zacks Rank #3 (Hold), which is a lower rating compared to peers like CNO Financial Group that carry a Zacks Rank #2 (Buy).
The company's stock has only gained 6.3% year-to-date, trailing the broader industry average growth of 6.1%.
Aflac Incorporated reported first-quarter earnings driven by strong new-business momentum in Japan, where sales surged 25.5% fueled by new products like the Onsen Tallett medical line and the Miraito cancer line. Adjusted earnings per diluted share rose to $1.75, or approximately $1.77 excluding foreign-exchange effects, representing about 6.6% year-over-year growth. This performance was aided by favorable reserve remeasurement gains of $82 million, which added roughly $0.04 per share and helped lift results above internal plans.
In the United States, sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention with premium persistency reaching 79.3%. Group voluntary products showed particular strength, helping stabilize and expand the U.S. franchise, with group segment growth of about 12.4% for the quarter. Company-wide profitability remained compelling, with adjusted return on equity at 12.8%, while Japan’s pretax margin climbed to 35% and the U.S. business held a solid pretax margin of 20.4%.
The company maintained a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum, and adjusted leverage of 21.2% within its target range. Aflac returned about $1.3 billion to shareholders through share repurchases and dividends, extending its multi-decade dividend growth streak. Strategic progress was noted at Aflac Re Bermuda, which assumed a block from Japan Post Insurance, positioning reinsurance as a future growth engine.
However, challenges included softer earned premiums in Japan, investment and reserve volatility, and a weaker Corporate & Other segment that slipped to roughly breakeven pretax adjusted earnings due to lower investment income and higher interest expenses. Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned. Management reaffirmed full-year guidance for Japan’s benefit ratio at 60%–63% and the U.S. at 42%–52%, signaling confidence in maintaining disciplined underwriting despite near-term headwinds from investment volatility and higher expenses.
📈 Japan sales surged 25.5% driven by new product launches.
🇺🇸 U.S. premiums grew 3.5% with a 79.3% persistency rate.
💰 Company returned $1.3B to shareholders via buybacks and dividends.
⚠️ Japan net earned premiums fell 3.8% in yen terms.
🏦 Aflac holds $3.4B liquidity, well above its minimum threshold.
📈 Aflac reported Q1 adjusted earnings per diluted share of $1.75, representing a 6.6% year-over-year increase.
🇯🇵 Japan sales surged 25.5% in the first quarter driven by new products like Onsen Tallett and the Miraito cancer line.
🇺🇸 U.S. sales grew 2.9% with net earned premium increasing 3.5%, supported by a premium persistency rate of 79.3%.
💰 The company returned approximately $1.3 billion to shareholders through share repurchases and dividends in the quarter.
📊 Japan's pretax margin climbed to 35%, up 320 basis points, while the U.S. business maintained a 20.4% pretax margin.
⚠️ Japan's net earned premiums fell 3.8% in yen terms due to lapses and paid-up policy migrations offsetting new sales.
🏦 Aflac holds $3.4 billion of unencumbered liquidity, which is roughly $2.4 billion above its internal minimum threshold.
🔄 The company assumed a reinsurance block from Japan Post Insurance to position reinsurance as a future growth engine.
⚖️ Total benefit ratios improved across segments, with Japan at 62.9% and the U.S. at 47.2%, aided by reserve remeasurement gains.
📉 The Corporate & Other segment slipped to breakeven pretax adjusted earnings due to lower investment income and higher interest expenses.
🏢 Aflac recorded $19 million in loan charge-offs and $24 million in impairments on real estate owned reflecting commercial real estate weakness.
📈 U.S. group products grew 12.4% for the quarter with a targeted mix of life, absence, disability, and consumer markets up roughly 25%.
🎯 Management reaffirmed full-year guidance for Japan's benefit ratio between 60% and 63% and the U.S. between 42% and 52%.
📉 An external reinsurance transaction modestly reduced Japan earnings by a mid-single-digit U.S. dollar amount in the quarter.
📉 The U.S. expense ratio rose to 38.3%, up 70 basis points year over year, driven by higher DAC amortization and commissions.
Bullish Signals
Aflac Japan sales jumped 25.5% driven by new products.
Adjusted EPS rose 6.6% to $1.75 with $82M reserve gains.
U.S. sales grew 2.9% and premium persistency hit 79.3%.
Aflac holds $3.4B unencumbered liquidity, well above internal minimums.
Shareholder returns totaled $1.3B via buybacks and dividends.
Japan's benefit ratio improved to 62.9% with favorable claims.
U.S. group products surged 12.4% with targeted mix growth of 25%.
Management reaffirmed full-year guidance for Japan and U.S. benefit ratios.
Aflac will maintain leverage within 20%-25% corridor.
Risk Factors
Japan net premiums fell 3.8% due to lapses and migrations.
$19M loan charge-offs and $24M real estate impairments hit earnings.
U.S. statutory impairments totaled $12M with income below expectations.
U.S. expense ratio rose 70 bps to 38.3%.
Aflac Japan earnings reduced by mid-single-digit USD via reinsurance.
Japan needs JPY 90B sales vs JPY 74B generated to break even.
Bullish Signals
Aflac Japan delivered a 25.5% jump in first-quarter sales, driven by new products like the Onsen Tallett medical product and the Miraito cancer line.
Adjusted earnings per diluted share rose to $1.75, representing about 6.6% growth year over year, with favorable reserve remeasurement gains of $82 million adding roughly $0.04 per share.
In the U.S., sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention as premium persistency reached 79.3%.
Company-wide profitability remained compelling with adjusted return on equity at 12.8%, and Japan's pretax margin climbed to 35%, up 320 basis points.
Aflac underscored a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum.
The company returned about $1.3 billion to shareholders in the quarter through roughly $1.0 billion of share repurchases and $315 million of dividends, extending its multi-decade dividend growth streak.
Japan's total benefit ratio improved to 62.9%, a 290-basis-point year-over-year decline, aided by favorable claims experience.
The U.S. group segment continued to gain traction with group products up about 12.4% for the quarter and targeted mix growth of roughly 25%.
Management reaffirmed full-year guidance for Japan's benefit ratio at 60%-63% and the U.S. at 42%-52%, signaling confidence in maintaining disciplined underwriting.
Aflac plans to keep adjusted leverage within its 20%-25% corridor and continue tactical capital deployment to support shareholder returns.
Risk Factors
Japan's net earned premiums fell 3.8% in yen terms, with underlying earned premiums down 1.3%, reflecting lapses and paid-up policy migrations that new sales have not yet fully offset.
Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned, reflecting continued weakness in commercial real estate markets.
U.S. statutory impairments totaled $12 million, alongside a small mortgage loan valuation allowance and variable investment income running about $14 million below long-term expectations.
The U.S. expense ratio rose to 38.3%, up 70 basis points year over year, driven by higher DAC amortization and commissions.
An external reinsurance transaction ceding first-sector business modestly reduced Aflac Japan earnings by a mid-single-digit U.S. dollar amount in the quarter, with expectations of slightly negative impact for the next few quarters.
Achieving flat earned premium in Japan would require about JPY 90 billion of annual sales, compared with roughly JPY 74 billion generated in 2025, signaling a need for further execution gains to offset policy lapses.
Aflac Incorporated reported first-quarter earnings driven by strong new business momentum in Japan, where sales surged 25.5% fueled by new products like the Onsen Tallett medical line and the Miraito cancer line. Adjusted earnings per diluted share rose to $1.75, or approximately $1.77 excluding foreign-exchange effects, representing about 6.6% year-over-year growth. This performance was aided by favorable reserve remeasurement gains of $82 million, which added roughly $0.04 per share and helped lift results above internal plans.
In the United States, sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention with premium persistency reaching 79.3%. Group voluntary products showed particular strength, helping stabilize and expand the U.S. franchise, with group segment growth of about 12.4% for the quarter. Company-wide profitability remained compelling, with adjusted return on equity at 12.8%, while Japan's pretax margin climbed to 35% and the U.S. business held a solid pretax margin of 20.4%.
The company maintained a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum, and adjusted leverage of 21.2% within its target range. Aflac returned about $1.3 billion to shareholders through share repurchases and dividends, extending its multi-decade dividend growth streak. Strategic progress was noted at Aflac Re Bermuda, which assumed a block from Japan Post Insurance, positioning reinsurance as a future growth engine.
However, challenges included softer earned premiums in Japan due to lapses and paid-up policy migrations, with net earned premiums falling 3.8% in yen terms despite new sales. The Corporate & Other segment slipped to roughly breakeven pretax adjusted earnings from a $43 million gain a year earlier due to lower investment income and higher interest expense. Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned, reflecting continued weakness in commercial real estate markets.
Management reaffirmed full-year guidance for Japan's benefit ratio at 60%–63% and the U.S. at 42%–52%, signaling confidence in maintaining disciplined underwriting. The company plans to keep adjusted leverage within its 20%–25% corridor and expects Japan sales to be roughly in line with 2025 levels, while aspiring to higher volumes to stabilize earned-premium growth over time. Executives cautioned that reserve remeasurement gains are partly timing-related and nonrecurring, meaning some favorable claims experience may not repeat in future quarters.
📈 Aflac Q1 adjusted EPS grew 6.6% to $1.75 with strong Japan sales.
💰 Company returned $1.3B to shareholders and holds $3.4B in liquidity.
📈 Aflac reported Q1 adjusted earnings per diluted share of $1.75, representing roughly 6.6% year-over-year growth.
🇯🇵 Japan sales surged 25.5% in the first quarter driven by new products like Onsen Tallett and the Miraito cancer line.
💰 Adjusted return on equity remained strong at 12.8% company-wide, with Japan's pretax margin climbing to 35%.
🇺🇸 U.S. sales increased 2.9% while net earned premium grew 3.5%, supported by a premium persistency rate of 79.3%.
💵 The company returned approximately $1.3 billion to shareholders through share repurchases and dividends in the quarter.
🏦 Aflac holds $3.4 billion of unencumbered liquidity, which is roughly $2.4 billion above its internal minimum threshold.
🔄 Strategic progress was made at Aflac Re Bermuda after assuming a block from Japan Post Insurance for diversification.
📉 Despite strong new sales, Japan's net earned premiums fell 3.8% in yen terms due to lapses and policy migrations.
⚠️ Reserve remeasurement gains contributed significantly to reported results but are considered nonrecurring and timing-related.
🏢 The Corporate & Other segment slipped to breakeven pretax adjusted earnings from a $43 million gain the prior year.
📉 Credit and real estate investments faced pressure with $19 million in loan charge-offs and $24 million in real estate impairments.
📈 U.S. group products grew about 12.4% for the quarter as initiatives improved agent onboarding and productivity.
🎯 Management reaffirmed full-year guidance for Japan's benefit ratio between 60% and 63%.
📉 The U.S. expense ratio rose to 38.3%, driven by higher DAC amortization and commissions.
📉 An external reinsurance transaction in Japan modestly reduced earnings, expected to turn neutral over the next few quarters.
📉 Corporate & Other earnings are sensitive to short-term interest rates, with expectations of slightly negative pretax earnings in Q2.
Bullish Signals
Aflac Japan sales jumped 25.5% driven by new products.
Adjusted EPS rose 6.6% to $1.75 with $82M gains.
U.S. sales grew 2.9% and premium persistency hit 79.3%.
Company-wide ROE reached 12.8% and Japan margin climbed to 35%.
Aflac holds $3.4B unencumbered liquidity, well above minimums.
Returned $1.3B to shareholders via buybacks and dividends.
Japan benefit ratio improved to 62.9% with better claims.
U.S. group products surged 12.4% with strong mix growth.
Management reaffirmed full-year guidance for Japan and U.S. ratios.
Aflac targets 20%-25% leverage and continues capital deployment.
Risk Factors
Nonrecurring $82M reserve gains may not repeat.
$19M loan charge-offs and $24M real estate impairments.
$12M U.S. statutory impairments and weak investment income.
U.S. expense ratio rose 70bps to 38.3%.
Aflac Japan earnings reduced by external reinsurance.
Japan needs JPY 90B sales vs JPY 74B generated.
Bullish Signals
Aflac Japan delivered a 25.5% jump in first-quarter sales, driven by new products like the Onsen Tallett medical product and the Miraito cancer line.
Adjusted earnings per diluted share rose to $1.75, representing about 6.6% growth year over year, with favorable reserve remeasurement gains of $82 million adding roughly $0.04 per share.
In the U.S., sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention as premium persistency reached 79.3%.
Company-wide profitability remained compelling with adjusted return on equity at 12.8%, and Japan's pretax margin climbed to 35%, up 320 basis points.
Aflac underscored a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum.
The company returned about $1.3 billion to shareholders in the quarter through share repurchases and dividends, extending its multi-decade dividend growth streak.
Japan's total benefit ratio improved to 62.9%, a 290-basis-point year-over-year decline, aided by favorable claims experience.
The U.S. group segment continued to gain traction with group products up about 12.4% for the quarter and targeted mix growth of roughly 25%.
Management reaffirmed full-year guidance for Japan's benefit ratio at 60%-63% and the U.S. at 42%-52%, signaling confidence in maintaining disciplined underwriting.
Aflac plans to keep adjusted leverage within its 20%-25% corridor and continue tactical capital deployment to support shareholder returns.
Risk Factors
Favorable reserve remeasurement gains of $82 million added roughly $0.04 per share, but executives cautioned these items are partly timing-related and nonrecurring, meaning some favorable claims experience may not repeat in future quarters.
Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned, reflecting continued weakness in commercial real estate markets.
U.S. statutory impairments totaled $12 million, accompanied by a small mortgage loan valuation allowance and variable investment income that ran about $14 million below long-term expectations.
The U.S. expense ratio rose to 38.3%, up 70 basis points year over year, driven by higher DAC amortization and commissions, which compressed margin expansion in the near term.
An external reinsurance transaction ceding first-sector business modestly reduced Aflac Japan earnings by a mid-single-digit U.S. dollar amount in the quarter, with management expecting it to be slightly negative to earnings for the next few quarters before turning neutral.
Achieving flat earned premium in Japan would require about JPY 90 billion of annual sales, compared with roughly JPY 74 billion generated in 2025, signaling that further execution gains are needed to fully offset policy lapses and paid-up movements.
Zacks Equity Research highlights five stocks within the Accident and Health Insurance industry, including Aflac Inc. (AFL), Unum Group (UNM), Globe Life (GL), Trupanion (TRUP), and Employers Holdings (EIG). The firm expects the sector to benefit from increased underwriting exposure and growing demand for group insurance, though it notes that higher inflation and rising medical costs could offset these positives. Soft pricing is anticipated to persist over the coming quarters, but a rise in lower-severity claims and the adoption of technology are expected to support industry operations.
The Accident and Health Insurance market, valued at approximately $300 billion in 2024, is projected to expand to roughly $420 billion by 2033. While pricing pressure remains due to inflation and demographic shifts like an aging population, the industry maintains profitability through solid reserves and prudent claims management. Technology adoption, particularly artificial intelligence and telemedicine, is expected to reduce claim expenses and improve risk profiling, although it may increase expense ratios.
Specific company outlooks include Aflac, which delivered a 7.86% earnings surprise on average and has an expected long-term earnings growth rate of 8.1%. Unum Group expects adjusted operating income per share between $8.60 and $8.90 for 2026 with premium growth of 4-7%, and it boasts a dividend yield better than the industry average. Globe Life anticipates mid-teens growth in net life and health sales driven by its Liberty National division. Trupanion, a pet insurer, shows strong analyst confidence with expected earnings increases of 17.8% for 2026 and 33% for 2027, following a 250% trailing four-quarter earnings surprise. Employers Holdings is noted as the 19th largest provider of workers' compensation insurance to small businesses in low-to-medium hazard industries, with consensus estimates suggesting a significant 139.8% increase in earnings for 2026 followed by a 5.6% increase in 2027. The industry currently trades at a price-to-book ratio of 1.68X, compared to the S&P 500 composite's 8.08X.
📈 Market projected to grow from $300B in 2024 to $420B by 2033.
⚠️ Inflation and medical costs may offset industry growth drivers.
🤖 AI and telemedicine adoption help insurers reduce claim expenses.
💵 Top stocks like Aflac and Unum show strong earnings potential.
📉 Industry trades at a low 1.68X price-to-book ratio vs S&P 500.
📈 The Zacks Accident and Health Insurance industry is expected to benefit from increased underwriting exposure and demand for group insurance.
⚠️ Higher inflation, rising medical costs, and soft pricing over recent quarters could offset some of the industry's positive drivers.
💰 The $300 billion A&H insurance market in 2024 is projected to expand to approximately $420 billion by 2033.
📉 Pricing pressure is expected to continue due to inflation, demographic changes, and efforts to retain market share.
🤖 Accelerated adoption of AI, data analytics, and telemedicine is helping insurers gain a competitive edge and reduce claim expenses.
🏆 The Zacks Accident and Health Insurance industry currently holds a Rank #102, placing it in the top 42% of all Zacks industries.
📊 The industry has outperformed its Finance sector year-to-date with a 5.5% gain against the sector's 0.9% decline.
💵 Aflac (AFL) is expected to benefit from strategic growth investments and the Argus buyout, though 2026 earnings estimates show a slight decrease.
📈 Unum Group (UNM) expects adjusted operating income per share between $8.60 and $8.90 for 2026 with premium growth of 4-7%.
🐾 Trupanion (TRUP), a pet insurer, delivered a trailing four-quarter earnings surprise of 250% on average with strong long-term growth potential.
🏭 Globe Life (GL) is driven by positive revenue trends in its Life and Health Insurance segments, particularly from Liberty National.
🛡️ Employers Holdings (EIG), the 19th largest workers' compensation provider, expects a significant 139.8% increase in 2026 earnings estimates.
📉 The industry trades at a trailing 12-month price-to-book ratio of 1.68X, significantly lower than the S&P 500 composite's 8.08X.
🔮 Analyst confidence is gradually increasing as aggregate earnings estimate revisions show positive growth potential for constituent companies.
Bullish Signals
Accident & Health industry to grow from $300B (2024) to $420B (2033).
The Accident and Health Insurance industry is projected to expand from $300 billion in 2024 to approximately $420 billion by 2033, reflecting strong long-term growth potential.
Aflac delivered a trailing four-quarter earnings surprise of 7.86% on average, demonstrating robust performance ahead of expectations.
Unum Group expects adjusted operating income per share between $8.60 and $8.90 for 2026, with premium growth anticipated in the 4-7% band driven by persistence and new sales.
Trupanion delivered a trailing four-quarter earnings surprise of 250% on average and holds a Growth Score of A, indicating strong upside potential.
Employers Holdings consensus estimates suggest a significant 139.8% year-over-year increase in earnings for 2026, followed by a 5.6% increase in 2027.
Globe Life's Liberty National division is expected to drive top-line growth with net life and health sales projected to grow in the mid-teens.
The industry benefits from increasing adoption of technology, including AI which could reduce workers' compensation claim expenses by about 45%.
Unum Group has an impressive dividend track record, having increased dividends 17 times in the last 16 years with an estimated 10-15% increase going forward.
Risk Factors
The Zacks Consensus Estimate for Aflac's 2026 earnings implies a year-over-year decrease of 4.9%, indicating near-term earnings contraction.
The consensus estimate for Aflac's 2026 earnings has moved south in the past 30 days, reflecting deteriorating analyst sentiment.
Higher inflation and rising medical costs are expected to offset industry positives, creating headwinds for profitability.
Soft pricing is anticipated to persist over the coming quarters, which could constrain premium growth and margins.
Efforts to retain market share will further increase pricing pressure, which might curb top-line growth.
The industry currently trades at a price-to-book ratio of 1.68X, significantly below the S&P 500 composite's 8.08X and the sector's 4.28X, suggesting potential undervaluation or market skepticism.
Over the past five years, the industry has traded as low as 0.97X, indicating significant volatility and downside risk in valuation multiples.
The article analyzes the Accident & Health Insurance industry, identifying it as a sector poised for growth due to increasing underwriting exposure and demand for group insurance, despite headwinds like inflation and rising medical costs. It highlights that the industry has maintained profitability through solid reserves and prudent claims management, with the market projected to expand from $300 billion in 2024 to $420 billion by 2033. Key trends shaping the sector include continued pricing pressure from demographic changes and healthcare cost increases, improving claims frequency due to better working conditions, and the adoption of technology such as AI and telemedicine to reduce claim expenses and operational costs.
The piece specifically focuses on five companies within the Zacks Accident and Health Insurance industry: Aflac Incorporated (AFL), Unum Group (UNM), Globe Life (GL), Trupanion (TRUP), and Employers Holdings, Inc. (EIG). It provides detailed outlooks for each, noting that they are currently rated with a Zacks Rank #3 (Hold). For Aflac, it mentions a 7.86% average earnings surprise and future growth expectations. Unum Group is noted for its strong dividend track record and projected operating income per share between $8.60 and $8.90 for 2026. Globe Life is highlighted for positive revenue trends driven by premium growth in life and health segments. Trupanion, a pet insurer, is cited for a massive 250% average earnings surprise and high expected growth rates. Employers Holdings is recognized as the 19th largest provider of workers' compensation insurance to small businesses with a solid market presence. The article concludes by noting that while the industry has outperformed its sector year-to-date, it currently trades at a lower price-to-book ratio compared to the broader S&P 500 composite.
📈 Market valued at $300B in 2024 is projected to reach $420B by 2033.
⚠️ Inflation and rising medical costs may offset industry growth trends.
🤖 AI and telemedicine adoption helps insurers reduce claim expenses.
💰 Industry trades at 1.68X price-to-book, significantly below S&P 500 average.
🏆 Top performers include Aflac, Unum, Trupanion, and Employers Holdings.
📈 The Zacks Accident and Health Insurance industry is expected to benefit from increased underwriting exposure and demand for group insurance.
⚠️ Higher inflation, rising medical costs, and soft pricing over recent quarters could offset some of the industry's positive trends.
💰 The A&H Insurance market, valued at approximately $300 billion in 2024, is projected to expand to about $420 billion by 2033.
📉 Pricing pressure is expected to continue due to inflation, rising medical costs, and demographic changes like an aging population.
🤖 The adoption of technology, including AI and telemedicine, is helping insurers gain a competitive edge and reduce claim expenses.
🏆 The Zacks Accident and Health Insurance industry currently holds a Rank #102, placing it in the top 42% of all Zacks industries.
📊 The industry has outperformed its broader Finance sector year-to-date with a collective gain of 5.5%, despite underperforming the S&P 500.
💵 On a trailing 12-month basis, the industry trades at a price-to-book ratio of 1.68X, significantly lower than the S&P 500 composite's 8.08X.
🏢 Aflac Incorporated (AFL) offers voluntary supplemental health and life insurance products with strategic growth investments in Japan and the U.S.
📉 Aflac delivered a trailing four-quarter earnings surprise of 7.86% on average, with an expected long-term earnings growth rate pegged at 8.1%.
🏥 Unum Group (UNM) provides long-term care and life insurance, boasting a dividend track record of increases for 17 times in the last 16 years.
📈 For 2026, Unum Group expects adjusted operating income per share between $8.60 and $8.90 with premium growth of 4-7%.
🐾 Trupanion (TRUP) operates in a large but underpenetrated pet insurance market worth $34.1 billion across multiple countries.
🚀 Trupanion delivered a trailing four-quarter earnings surprise of 250% on average and has a Growth Score of A.
🏭 Globe Life (GL) provides individual life and supplemental health insurance, with strong performance expected from its American Income and Liberty National divisions.
🛡 Employers Holdings (EIG) is the 19th largest provider of workers' compensation insurance to small businesses in low-to-medium hazard industries.
📈 The consensus estimate for Employers Holdings suggests a massive 139.8% year-over-year earnings increase for 2026, followed by a 5.6% increase in 2027.
Bullish Signals
Industry benefits from increased underwriting exposure and demand.
Profitability streak maintained with solid reserves and stable trends.
Market projected to expand from $300B to $420B by 2033.
Aflac shows 7.86% earnings surprise and 8.1% long-term growth.
Unum Group expects 10-15% dividend increase with 11.3% growth.
Globe Life drives growth with mid-teens sales expansion.
Trupanion targets $34.1B underpenetrated market with 250% earnings surprise.
Zacks Industry Rank #102 places sector in top 42%.
Risk Factors
Aflac 2026 earnings imply 4.9% YoY decrease.
Analyst confidence weakened as estimates dropped 30 days.
Industry trades at 1.68X P/B vs S&P 500's 8.08X.
Sector underperformed S&P 500 YTD, rising only 5.5%.
Favorable loss development may curb Aflac top-line growth.
Tech spending escalates industry expense ratios, hurting profits.
Bullish Signals
The Zacks Accident and Health Insurance industry is expected to benefit from an increase in underwriting exposure, driven by increasing demand for group insurance and prudent underwriting standards.
Per a CBIZ report, the industry has maintained its profitability streak, reflecting solid reserves, prudent claims management, stable loss trends, and fewer claims.
The A&H Insurance market is projected to expand from about $300 billion in 2024 to about $420 billion by 2033, indicating strong long-term growth potential.
Aflac delivered a trailing four-quarter earnings surprise of 7.86% on average and has an expected long-term earnings growth rate pegged at 8.1%.
Unum Group estimates a 10-15% increase in dividends going forward, having increased dividends 17 times in the last 16 years, with a long-term earnings growth rate of 11.3%.
Globe Life's strong performance in its American Income and Liberty National divisions is expected to drive top-line growth, with net life and health sales projected to grow in the mid-teens for Liberty National.
Trupanion operates in a total addressable market worth $34.1 billion which is underpenetrated, and delivered a trailing four-quarter earnings surprise of 250% on average.
Employers Holdings has a consensus estimate for 2026 earnings suggesting a 139.8% year-over-year increase, with the estimate moving nearly 2.3% north in the past 30 days.
The Zacks Accident and Health Insurance industry currently carries a Zacks Industry Rank #102, placing it in the top 42% of 243 Zacks industries.
Risk Factors
The Zacks Consensus Estimate for Aflac's 2026 earnings implies a year-over-year decrease of 4.9%, indicating near-term earnings contraction.
Aflac's consensus estimate has moved south in the past 30 days, suggesting weakening analyst confidence or deteriorating expectations.
The industry is currently trading at a trailing 12-month price-to-book ratio of 1.68X, which is significantly lower than the Zacks S&P 500 composite's 8.08X and the sector's 4.28X, indicating potential undervaluation or market skepticism.
The industry has underperformed the Zacks S&P 500 composite year to date, rising only 5.5% compared to the broader index's gain of 9.1%.
Sustained favorable loss development and beneficial loss frequency are expected to put downward pressure on pricing, which might curb top-line growth for Aflac.
Higher spending on technological advancements, including AI and automation, will result in escalated expense ratios for the industry, potentially impacting profitability.
Japan Post Holdings Co., Ltd. sold a small portion of its stake in Aflac Inc., reporting the disposal of 24,300 shares totaling approximately $2.8 million on May 12, 2026. The transactions occurred across two separate deals, with weighted average prices ranging between $115.08 and $116.26 per share, executed while Aflac's stock traded near its 52-week high of $119.32. Following the sales, Japan Post Holdings retains a beneficial ownership of 51,588,545 shares, held indirectly through J&A Alliance Holdings Corporation as trustee for the J&A Alliance Trust.
In related corporate news, Aflac reported mixed results for its first quarter of 2026, with adjusted earnings per share of $1.75 falling short of the $1.80 consensus forecast, though revenue of $4.35 billion beat expectations at $4.18 billion. During the annual meeting, shareholders approved all proposals except one seeking an independent board chairman, leading to the election of eleven directors and the ratification of KPMG LLP as the independent registered public accounting firm until the end of 2026. Additionally, Aflac announced plans to open a new office in South Portland, Maine, intended to administer claims for the state's Paid Family and Medical Leave program.
🏢 Japan Post sold $2.8M worth of 24,300 Aflac shares near the 52-week high.
💰 Analysts suggest Aflac stock remains undervalued despite recent earnings miss on EPS forecasts.
✅ Shareholders approved all annual meeting proposals except the independent board chairman request.
🏢 Japan Post Holdings Co., Ltd. sold $2,818,084 worth of Aflac common stock on May 12, 2026.
📉 The sale consisted of 24,300 shares executed in two separate transactions with prices ranging from $115.08 to $116.26 per share.
📈 These sales occurred while Aflac stock was trading near its 52-week high of $119.32.
💰 InvestingPro analysis suggests that despite the recent price levels, Aflac's stock remains undervalued relative to its Fair Value.
🏦 Following the sale, Japan Post Holdings retains beneficial ownership of 51,588,545 shares held via J&A Alliance Holdings Corporation.
📉 Aflac reported first-quarter 2026 adjusted earnings per share of $1.75, missing analyst forecasts of $1.80.
💵 However, the company beat revenue expectations by reporting $4.35 billion against an anticipated $4.18 billion.
✅ At the annual meeting, shareholders approved all proposals except one seeking an independent board chairman.
👥 Eleven directors were elected to Aflac's board during the recent annual shareholder meeting.
⚖️ KPMG LLP was ratified as the independent registered public accounting firm through the end of 2026.
🏡 Aflac announced plans to open a new office in South Portland, Maine.
🤝 The new Maine facility will specifically administer claims for the state's Paid Family and Medical Leave program.
Bullish Signals
Aflac shares trade near 52-week high of $119.32.
Undervalued relative to Fair Value with potential upside.
Q1 2026 revenue beat expectations at $4.35 billion.
Passed all shareholder proposals with eleven directors elected.
New Maine office signals expansion for paid leave program.
Risk Factors
Japan Post sold $2.8M (24,300 shares) of Aflac stock.
Institutional selling occurred near the $119.32 52-week high.
Q1 2026 EPS missed forecasts at $1.75 versus $1.80.
Aflac shares are trading near their 52-week high of $119.32, indicating strong investor sentiment and price momentum.
InvestingPro analysis suggests that despite Japan Post Holdings selling stock, Aflac remains undervalued relative to its Fair Value, presenting a potential upside opportunity for buyers.
In the first quarter of 2026, Aflac exceeded revenue expectations by reporting $4.35 billion against the anticipated $4.18 billion, demonstrating top-line strength.
Aflac successfully passed all shareholder proposals at its annual meeting and had eleven directors elected to the board, reflecting positive corporate governance dynamics.
The opening of a new office in South Portland, Maine, signals geographic expansion to administer claims for the state's Paid Family and Medical Leave program.
Risk Factors
Japan Post Holdings sold $2.8 million worth of Aflac stock (24,300 shares), a significant reduction in its position by a major shareholder.
The large institutional selling occurred while the stock was near its 52-week high of $119.32, raising potential profit-taking concerns at these elevated levels.
Aflac's first-quarter 2026 adjusted earnings per share (EPS) missed analyst forecasts at $1.75 versus the expected $1.80, indicating weaker-than-anticipated profitability.
The failed shareholder proposal to appoint an independent board chairman highlights lingering internal governance concerns and lack of structural changes to address shareholder dissent.
AFL (Baylor University) head coach Steve Sarkisian has announced that the Baylor Bears will open their 2026 season against the Auburn Tigers in a neutral-site matchup at Mercedes-Benz Stadium in Atlanta, Georgia on Labor Day Weekend, September 5. The game marks the second consecutive year these two programs meet, though this is the first time they are playing as non-conference opponents after previous meetings involving conference scheduling complexities. Baylor aims to avenge a 38-24 loss suffered last season when the game was held at McLane Stadium in Waco, where Auburn's Jackson Arnold rushed for 137 yards and two touchdowns while QB Sawyer Robertson threw for 419 yards and three scores despite defensive struggles by the Bears.
The Bulldogs will look to improve on their recent performance with a significantly revamped roster featuring 32 incoming transfers and new quarterback DJ Lagway, a former Florida signal-caller entering his first season at Baylor under Sarkisian's direction. In contrast, Auburn has hired a new coaching staff led by Joe Klanderman, who will make his debut in this opening game against the Bears, while former Baylor transfer Bryson Washington joins the Tigers' offense for their first appearance against his old program. This neutral-site arrangement is particularly advantageous for Baylor, who previously traveled to Waco for the matchup, whereas Auburn coach Dave Aranda prefers playing in Atlanta over a potential home game at Jordan-Hare Stadium.
🏈 Baylor vs. Auburn plays at Mercedes-Benz Stadium during Labor Day Weekend.
🔄 This marks the second consecutive season opening matchup between the rivals.
🤝 Former Baylor player Bryson Washington transfers to face his old team.
🛡️ Baylor aims for revenge with QB DJ Lagway leading the offense.
🏈 Baylor and Auburn have landed a prime slot for their season opener on ABC during Labor Day Weekend.
🏟️ The matchup will be played at Mercedes-Benz Stadium in Atlanta, Georgia as a neutral-site game.
🔄 This marks the second consecutive year these two teams will open their seasons against each other.
⚔️ The series history between the schools is currently deadlocked with Baylor holding a 2-2-1 advantage.
🛡️ Baylor aims to avenge last year's 38-24 loss in Waco, where Auburn's Jackson Arnold ran for 137 yards and two touchdowns.
👦 Baylor quarterback Sawyer Robertson performed well against Auburn last season with 419 passing yards and three scores.
🔄 Looking ahead to the 2026 season, Auburn will feature a new coaching staff while Baylor brings in 32 incoming transfers.
🏃 Former Florida QB DJ Lagway is set to lead Baylor's offense for the upcoming campaign.
🤝 Auburn player Bryson Washington is leaving Baylor to join the Tigers for his first game against his former team.
🛡️ Joe Klanderman will lead a new-look defense for Baylor in the opener, which Washington has not seen.
🎯 Baylor returns key sophomores including Michael Turner and Caden Knighten for the season opener.
📅 The teams are scheduled to step on the field at Mercedes-Benz Stadium on September 5.
Aflac (AFL) is facing a nuanced analyst environment characterized by mixed price target adjustments and cautious outlooks that diverge on the pace of growth while maintaining neutral or equal-weight ratings. Major institutions like Wells Fargo have increased their fair value estimates for AFL to US$118, citing refreshed earnings frameworks for 2027 and 2028 that support current valuations if execution meets expectations. Conversely, several firms including Piper Sandler, Barclays, Mizuho, and UBS have trimmed price targets by US$2 to US$5, reflecting concerns regarding execution risks and tighter earnings guidance without necessarily downgrading their ratings. Keefe Bruyette has also taken a balanced approach by reinitiating coverage with a Market Perform rating and slight increases, suggesting the risk-reward profile remains neutral rather than skewed toward significant expansion.
Specific operational developments continue to shape the investment narrative, including a strategic coinurance agreement between Aflac Re Bermuda Ltd. and Japan Post Insurance Co. Ltd. regarding whole life annuities starting March 31, 2026, where Japan Post will service and administer the policies. Additionally, the company is expanding its product suite by adding long-term care riders to its Group Life Term to 120 offering, while simultaneously broadening distribution reach through a new affiliation with Empower Brokerage that enables over 8,000 agents to sell individual and group Aflac policies. Shareholder returns remain a focus as the company executed a significant stock buyback program between October and December 2025, repurchasing approximately 7.25 million shares for US$800.12 million, marking the final tranche of a larger authorization announced in 2017.
Underlying these corporate actions are specific valuation inputs and forward-looking assumptions that analysts have recently recalibrated. The consensus fair value remains around US$111.86 per share, though long-term revenue growth expectations have been notably revised downward from 1.46% to a projected decline of 0.14%. Meanwhile, net profit margin assumptions saw a minor uptick to 20.86%, and the future P/E multiple is expected to shift slightly higher to 16.67x against a required discount rate of 6.98%. The overarching narrative acknowledges that while new cancer products in Japan and digital underwriting initiatives offer cross-sell potential, significant risks persist due to premium pressure in the Japanese market, elevated technology and expense ratios, currency exposure, and softer sales momentum in the United States.
📉 Analysts trim earnings growth assumptions but maintain mixed price target views.
💰 Aflac spent over $800M on share buybacks in late 2025.
🛡️ Strategic moves include new care riders, Japan Post affiliation, and agent partnerships.
📉 Analysts are resetting price targets for Aflac (AFL), with some firms trimming targets by US$2 to US$5 while others, like Wells Fargo, have lifted theirs to US$118.
🤔 The market narrative is shifting from big moves to small adjustments, reflecting cautious commentary that pulls earnings expectations down while maintaining neutral ratings.
📅 Wells Fargo specifically refreshed its 2027 and 2028 EPS frameworks, suggesting a longer runway of earnings assumptions to support current valuations if guidance is met.
⚠️ Piper Sandler, Barclays, Mizuho, and UBS have adopted more cautious stances around execution and earnings, even though they have not downgraded their stock ratings aggressively.
🔄 Keefe Bruyette reinitiated coverage at Market Perform with a slight price target increase, indicating that analysts view the risk-reward profile as balanced rather than skewed toward growth.
💰 Aflac completed a share repurchase program between October 1 and December 31, 2025, buying back over 7.2 million shares for US$800.12 million.
🤝 Aflac Re Bermuda Ltd agreed with Japan Post Insurance to reinsure whole life annuities through coinsurance, with administration continuing from Japan Post starting March 31, 2026.
🛡️ The company added a long-term care rider to its Group Life Term product, combining term life coverage with benefits for home or facility-based care.
🤝 Empower Brokerage entered an affiliation with Aflac, enabling over 8,000 agents to sell individual and group policies with support on contracting and commissions.
📊 Simply Wall St's fair value estimate remains steady at US$111.86 per share with no change in the implied intrinsic value used in their model.
📉 Analysts reduced their long-term revenue growth assumption significantly, moving from 1.46% growth to a projected 0.14% decline.
📈 The net profit margin input adjusted slightly upward from 20.75% to 20.86%, and the future P/E multiple shifted from 16.53x to 16.67x.
🇯🇵 Key risks identified include premium pressure in Japan, higher technology and expense ratios, currency exposure, and slower momentum in U.S. sales.
💻 Future growth is being driven by new cancer products in Japan, modular coverage options, and expanded group benefits that widen the addressable market.
📱 Digital transformation plays a major role through digital underwriting, Gen AI tools, and direct-to-consumer channels in both Japan and the U.S.
⚠️ This summary is based on historical data and analyst forecasts from Simply Wall St and is not intended as financial advice or a recommendation to buy or sell stock.
Bullish Signals
Wells Fargo raised target to US$118 on fair value alignment.
Analyst forecasts extended through 2028 supporting current valuation.
Keefe Bruyette reinitiated coverage with small price target increase.
Empower Brokerage affiliation enables 8,000 agents to sell policies.
Aflac repurchased 7.25 million shares for US$800m commitment.
New long-term care rider added to Group Life Term product.
Risk Factors
Major analysts including Piper Sandler and UBS cut Aflac targets by $2-$5.
Long-term growth downgraded from 1.46% gain to 0.14% decline projections.
Key risks: Japan premium pressure, higher tech costs, and currency exposure.
Mixed analyst sentiment leads to mostly neutral or market perform ratings.
Valuation P/E multiple assumptions adjusted slightly lower to 16.67x.
Bullish Signals
Wells Fargo lifted its Aflac price target to US$118 from US$109 and maintains an Equal Weight rating, signaling continued alignment with fair value.
Analyst frameworks have been refreshed for 2027 and 2028 EPS, extending the runway of earnings assumptions to support current valuation arguments.
Keefe Bruyette reinitiated coverage at Market Perform and made a small price target increase, indicating that some analysts view risk and reward as balanced with room for upside.
Empower Brokerage began an affiliation with Aflac, enabling over 8,000 partnering agents to sell Aflac individual and group policies.
From October 1, 2025 to December 31, 2025, Aflac repurchased approximately 7.25 million shares for US$800.12m, demonstrating commitment to shareholder capital return.
Aflac is expanding its product offerings by adding a long term care rider to its Group Life Term to 120 product for home or facility based care.
Risk Factors
Several major analysts including Piper Sandler, Barclays, Mizuho, and UBS have trimmed their Aflac price targets by US$2 to US$5, reflecting cautious stances regarding execution and earnings performance.
The company's long-term revenue growth assumption has been significantly downgraded from a 1.46% growth rate to a projected 0.14% decline in the financial model.
Key risks explicitly tied to Aflac include ongoing premium pressure in Japan, higher technology and expense ratios, currency exposure, and slower sales momentum in the U.S.
While some analysts like Keefe Bruyette increased targets, others see the risk-reward balance as skewed toward caution rather than strong growth, maintaining only neutral or market perform ratings.
The valuation model has adjusted future P/E multiple assumptions to 16.67x, which implies a shift in expected future earnings performance compared to previous estimates of 16.53x.
Aflac Incorporated (AFL) reported first-quarter 2026 adjusted earnings per share of $1.75, missing analyst estimates by 2.9%, though its bottom line still grew 5.4% year over year. Adjusted revenues fell 1.9% year over year to $4.2 billion, trailing the consensus mark due primarily to lower net investment income and adverse exchange rate impacts in Japan; however, this downside was partially offset by stronger sales growth within the U.S. unit. Net benefits and claims declined 5.8% year over year to $1.8 billion, while acquisition and operating expenses decreased slightly by 1.5% to $1.3 billion, driving pre-tax earnings up significantly to $1.2 billion from just $145 million in the prior-year quarter.
Geographically, Aflac Japan’s adjusted revenues dropped 4.4% year over year to $2.2 billion, missing consensus expectations, driven by a 6.4% decline in net earned premiums. Despite these underwriting challenges, the segment saw investment income rise 0.9% and new annualized premium sales surge 25.5% year over year, bolstered by strong performance of specific product lines like Anshin Palette and Miraito. Conversely, Aflac U.S. delivered solid growth with adjusted revenues increasing 3.4% to $1.8 billion and net earned premiums advancing 3.5% to $1.6 billion, both metrics beating analyst consensus estimates.
Balance sheet and capital allocation figures show Aflac exiting the quarter with total investments and cash of $103.2 billion, down slightly from year-end levels, while adjusted debt dropped 1.2% to $7.6 billion. This deleveraging improved the adjusted debt-to-adjusted capitalization ratio to 21.2%, reflecting a 20 basis point improvement from the previous year-end figure. Shareholders' equity grew 1.6% to $30 billion, leading to an adjusted book value per share increase of 5.7% to $54.96 and a year-over-year ROE improvement to 16.4% (excluding foreign currency impacts). Additionally, the company executed a $1 billion share buyback program in Q1 and paid dividends totaling $315 million during the quarter.
Looking ahead, management maintains its forward guidance for benefit ratios ranging from 60-63% in Japan and 48-52% in the U.S. for the current year. Expense ratios are reiterated at 20-23% for Japan and 36-39% for the U.S., while underlying earned premiums are expected to decline slightly by 1-2% globally. Net earned premiums for the U.S. unit are projected to grow, albeit at the lower end of the 3-6% range. Aflac currently holds a Zacks Rank #3 (Hold) based on these mixed but stabilizing quarterly results and future outlooks.
📉 Aflac missed earnings and revenue estimates due to investment income drops and FX fluctuations.
🇺🇸🇯🇵 U.S. sales beat expectations while Japan revenue fell despite strong new premium growth.
💰 The company executed a $1B buyback, paid a dividend, and improved its ROE.
📉 Aflac reported first-quarter 2026 adjusted earnings per share of $1.75, missing analyst estimates by 2.9%.
💰 Despite the miss, total bottom line earnings improved 5.4% year over year to pre-tax earnings of $1.2 billion.
📊 Adjusted revenues declined 1.9% year over year to $4.2 billion, missing the consensus estimate by 2.1%.
🌏 Lower net investment income and exchange rate fluctuations negatively impacted quarterly performance.
🇺🇸 Higher U.S. unit sales partially offset the downside risks from investment and FX factors.
💸 Adjusted net investment income fell 1.2% year over year to $902 million for the quarter.
📉 Net benefits and claims decreased 5.8% year over year to $1.8 billion, while expenses dropped 1.5%.
🇯🇵 Aflac Japan adjusted revenues dipped 4.4% to $2.2 billion, missing the Zacks consensus estimate.
💡 New annualized premium sales in Japan surged 25.5% year over year driven by specific product lines.
🇺🇸 Aflac U.S. adjusted revenues grew 3.4% to $1.8 billion, beating analyst expectations.
📈 The U.S. unit net earned premiums advanced 3.5% year over year, outpacing the consensus mark.
💹 The company ended Q1 with total investments and cash of $103.2 billion, down slightly from year-end.
🏦 Adjusted debt decreased to $7.6 billion, improving the debt-to-capitalization ratio by 20 basis points.
💰 Aflac executed a $1 billion share buyback and paid a $315 million dividend in Q1 2026.
📈 Adjusted return on equity improved to 16.4% year over year, excluding foreign currency impacts.
🏭 Management projects the Japan unit benefit ratio to remain between 60-63% for 2026.
🔍 The U.S. unit is expected to see net earned premiums at the lower end of the 3-6% range in 2026.
📉 Competitor RenaissanceRe beat estimates with operating income of $13.75 per share in Q1 2026.
⚖️ AMERISAFE missed estimates with adjusted earnings of 50 cents, down 16.7% year over year.
💵 Hartford reported core EPS of $3.09, up 40.5% but missing the consensus estimate by 6.1%.
Bullish Signals
Aflac adjusted EPS improved 5.4% year over year.
Total pre-tax earnings surged to $1.2 billion.
Aflac U.S. revenues grew 3.4% to $1.8 billion.
Net earned premiums in the U.S. rose 3.5% to $1.6 billion.
U.S. unit sales totaled $318 million, up 2.9%.
Adjusted return on equity improved to 16.4%.
Company executed $1 billion buyback and $315M dividend.
Adjusted debt reduced to $7.6 billion.
Debt-to-capitalization ratio improved to 21.2%.
Adjusted book value per share increased 5.7%.
Risk Factors
Q1 adjusted EPS missed estimate by 2.9%.
Adjusted revenues fell 1.9% YoY.
Aflac Japan revenue dipped 4.4%.
Aflac Japan earnings missed consensus mark.
Management expects premium decline in 2026.
Total investments decreased $0.6 billion.
The Hartford EPS missed by 6.1%.
Bullish Signals
Aflac's adjusted EPS improved 5.4% year over year despite missing consensus estimates, demonstrating underlying profitability strength.
Total pre-tax earnings surged to $1.2 billion from a mere $145 million in the prior-year quarter, marking a dramatic recovery.
Aflac U.S. unit revenues grew 3.4% year over year to $1.8 billion and beat the consensus estimate by 0.3%.
Net earned premiums in the U.S. advanced 3.5% year over year to $1.6 billion, surpassing the consensus mark of $1.5 billion.
U.S. unit sales totaled $318 million, up 2.9% year over year, driven by higher sales of group products.
Aflac's adjusted return on equity improved 80 basis points year over-year to a robust 16.4%, excluding foreign currency impacts.
The company executed a significant $1 billion share buyback in the first quarter while paying a $315 million dividend, signaling confidence in capital allocation.
Aflac reduced its adjusted debt to $7.6 billion, a 1.2% decrease from the prior year-end figure, strengthening its balance sheet.
The debt-to-capitalization ratio improved by 20 basis points to 21.2%, indicating better leverage management.
Adjusted book value per share increased 5.7% year over year to $54.96, reflecting growing intrinsic value for shareholders.
Risk Factors
Aflac's Q1 adjusted EPS of $1.75 missed the Zacks Consensus Estimate by 2.9%, indicating weaker-than-expected profitability.
Adjusted revenues declined 1.9% year over year to $4.2 billion, with the top line missing the consensus mark by 2.1%. This revenue contraction was driven by lower net investment income and unfavorable exchange rates.
Aflac Japan's adjusted revenues dipped 4.4% year over year to $2.2 billion, significantly missing the Zacks Consensus Estimate of $2.3 billion.
Net earned premiums for Aflac Japan slipped 6.4% year over year to $1.6 billion and missed the consensus mark by 3.1%, highlighting deteriorating core business performance in its largest segment.
Aflac Japan's pretax adjusted earnings of $759 million missed the consensus mark of $800.9 million, despite an increase of 5.1% year over year.
Management expects a decline in underlying earned premiums of 1-2% for Aflac Japan in 2026, suggesting continued headwinds in the domestic market.
Adjusted debt to adjusted capitalization is 21.2%, though the company's total investments and cash decreased to $103.2 billion from the year-end level of $103.8 billion.
Competitors such as AMERISAFE also missed consensus estimates, with operating revenues missing by 0.9% due to higher expenses and weaker underwriting margins.
The Hartford Insurance Group missed its Q1 EPS consensus by 6.1% due to less favorable prior-year reserve development and pressure in Employee Benefits.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)